Compositions and methods for treating cancers associated with etbr activation

Abstract

The description provides compositions and methods for treating ETBR-related cancer. In certain aspects, the description provides a delivery system for the controlled, systemic release of at least one of ETBR antagonists, caspase-8 inhibitors, or a combination thereof, optionally including an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide or a combination thereof. The compositions described are useful for the treatment of certain cancers, including, e.g., breast cancer, malignant melanoma, squamous cell carcinoma, glioblastoma, as well as others. In addition, the description provides a delivery system for the controlled release of at least one of ETBR antagonists, caspase-8 inhibitors or a combination thereof, optionally including at least one of an ETAR antagonist, an anti-PD-1 antibody, a bRAF inhibitor, niacinamide, or a combination thereof, to the central nervous system that are useful for treating cancers that have spread to the brain.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS / PATENTS[0001]This application claims priority to U.S. Provisional Application Ser. No. 62 / 200,181, filed on Aug. 3, 2015, entitled “COMPOSITIONS AND METHODS FOR TREATING CANCERS ASSOCIATED WITH ETBR ACTIVATION”, the entire contents of which are incorporated herein by reference in its entirety and for all purposes.INCORPORATION BY REFERENCE[0002]In compliance with 37 C.F.R. §1.52(e)(5), the sequence information contained in electronic file name: 1514985_101US_Sequence_Listing_ST25.txt; size 649 B; created on: 2 Aug. 2016; using Patent-In 3.5, and Checker 4.4.0 is hereby incorporated herein by reference in its entirety.BACKGROUND[0003]1. Field of the Discovery[0004]The present description relates to a controlled delivery therapeutic system for the treatment of cancer, a method of treating cancer, and diagnostic screening methods. In particular, presently described are compositions and methods for administering a treatment for cancer, e.g., malig...

AI Technical Summary

Benefits of technology

The present patent describes a therapeutic composition or formulation that includes an ETBR antagonist for the treatment of cancer, particularly melanoma, metastatic melanoma, squamous cell carcinoma, glioblastoma, or a combination of these cancers. The composition also includes a caspase-8 inhibitor and / or an ETAR antagonist, which may act synergistically with the ETBR antagonist to provide better treatment outcomes. The dosage of the ETBR antagonist may range from 0.1 μg to 5000 μg, while the dosage of the caspase-8 inhibitor may range from 0.1 μg to 5000 μg. The composition may also include an anti-PD1 antibody, a bRAF inhibitor, niacinamide, or a combination of these agents. Overall, the patent provides a therapeutic approach for treating ETBR-related cancers by targeting the ETBR receptor.

Problems solved by technology

The primary treatment approach for malignant melanoma is surgical resection, and radiation, which carries a 50% recurrence rate within a year, and potential post radiation cognitive deficits.9 Malignant melanomas that are in excess of 0.76 mm in thickness carry a significant risk for metastasis.

However, current melanoma therapies are approved only for advanced disease.

Despite progress in cancer therapy development, including for melanoma and SCC, a significant unmet need remains for effective treatments.

However, there are currently no melanoma drugs on the market that target ETBR.

Images